Literature DB >> 1739617

Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA).

M Hosono1, K Endo, H Sakahara, Y Watanabe, T Saga, T Nakai, C Kawai, A Matsumori, T Yamada, T Watanabe.   

Abstract

Human anti-murine antibody (HAMA) response is a serious problem in the repeated infusion of murine monoclonal antibodies (MoAbs). HAMA positive sera were obtained from seven patients with colorectal cancer, pancreas cancer, malignant melanoma or myocardial infarction who had previously received radiolabelled MoAbs. The nature of HAMA was analysed using size exclusion high performance liquid chromatography (HPLC) after incubating with radiolabelled MoAbs including IgG, Fab or human/mouse chimeric Abs. Immune complexes composed of HAMA and MoAbs were formed. The percentage of radioactivity with a high molecular weight was related to HAMA levels determined by enzyme linked immunosorbent assay. Most radioactivity present in immune complex shifted to the antibody fraction after the addition of normal murine serum. All of seven sera were reactive with all four murine IgGs and this suggests that HAMA in these patients recognised the constant region of MoAbs. In one patient, HAMA was considered to recognise the variable region and to be anti-idiotypic. There was no significant binding with human/mouse chimeric Abs in any HAMA positive serum, although five out of seven patients were reactive with murine MoAb Fab, indicating that HAMA was composed of Abs responsive to the CH1 or CL region of murine IgG. These results suggest that (1) HAMA was composed of Ab responsive to Fc portion and/or CH1 or CL region of murine IgG, and (2) human/mouse chimeric Abs look promising in the repeated infusion of MoAb in HAMA positive patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1739617      PMCID: PMC1977718          DOI: 10.1038/bjc.1992.41

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications.

Authors:  J C Reynolds; S Del Vecchio; H Sakahara; M E Lora; J A Carrasquillo; R D Neumann; S M Larson
Journal:  Int J Rad Appl Instrum B       Date:  1989

3.  Effect of DTPA conjugation on the antigen binding activity and biodistribution of monoclonal antibodies against alpha-fetoprotein.

Authors:  H Sakahara; K Endo; T Nakashima; M Koizumi; H Ohta; K Torizuka; T Furukawa; Y Ohmomo; A Yokoyama; K Okada
Journal:  J Nucl Med       Date:  1985-07       Impact factor: 10.057

4.  Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody.

Authors:  R F Meredith; A F LoBuglio; W E Plott; R A Orr; I A Brezovich; C D Russell; E B Harvey; M V Yester; A J Wagner; S A Spencer
Journal:  J Nucl Med       Date:  1991-06       Impact factor: 10.057

5.  Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.

Authors:  L Monod; A C Diserens; C V Jongeneel; S Carrel; P Ronco; P Verroust; N de Tribolet
Journal:  Int J Cancer       Date:  1989-11-15       Impact factor: 7.396

6.  [111In-antimyosin Fab scintigraphy in cardiovascular diseases: (multicenter clinical trial)].

Authors:  C Kawai; A Matsumori; T Nishimura; K Endo
Journal:  Kaku Igaku       Date:  1990-12

7.  Immunoscintigraphy of colon carcinoma.

Authors:  J F Chatal; J C Saccavini; P Fumoleau; J Y Douillard; C Curtet; M Kremer; B Le Mevel; H Koprowski
Journal:  J Nucl Med       Date:  1984-03       Impact factor: 10.057

8.  Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.

Authors:  Y Nishimura; M Yokoyama; K Araki; R Ueda; A Kudo; T Watanabe
Journal:  Cancer Res       Date:  1987-02-15       Impact factor: 12.701

9.  Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase.

Authors:  M Letarte; S Vera; R Tran; J B Addis; R J Onizuka; E J Quackenbush; C V Jongeneel; R R McInnes
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

10.  Immunoscintigraphy and pharmacokinetics of indium-111-labeled ZME-018 monoclonal antibody in patients with malignant melanoma.

Authors:  M Koizumi; K Endo; Y Watanabe; T Saga; H Sakahara; J Konishi; Y Arano; Y Miyachi; M Kashihara-Sawami; S Imamura
Journal:  Jpn J Cancer Res       Date:  1988-08
View more
  7 in total

1.  Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rγc KO. NOD).

Authors:  Mirian Mendoza; Angela Ballesteros; Qi Qiu; Luis Pow Sang; Soumya Shashikumar; Sofia Casares; Teodor-D Brumeanu
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

2.  Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.

Authors:  Elisa Vigna; Cristina Chiriaco; Simona Cignetto; Lara Fontani; Cristina Basilico; Fiorella Petronzelli; Paolo M Comoglio
Journal:  Mol Oncol       Date:  2015-06-05       Impact factor: 6.603

3.  A canine-derived chimeric antibody with high neutralizing activity against canine parvovirus-2.

Authors:  Lixuan Zhou; Hongchao Wu; Mengmeng Du; Huanhuan Song; Ningning Huo; Xiao Chen; Xiaorui Su; Weiguo Li; Lulu Wang; Jie Wang; Baicheng Huang; Feifei Tan; Kegong Tian
Journal:  AMB Express       Date:  2022-06-15       Impact factor: 4.126

4.  T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Authors:  Marcela V Maus; Andrew R Haas; Gregory L Beatty; Steven M Albelda; Bruce L Levine; Xiaojun Liu; Yangbing Zhao; Michael Kalos; Carl H June
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

Review 5.  Consensus on the treatment of pancreatic cancer in Spain.

Authors:  M Hidalgo; A Abad; E Aranda; L Díez; J Feliu; C Gómez; A Irigoyen; R López; F Rivera; C Rubio; J Sastre; J Tabernero; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

6.  Radioimmunodetection with 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer.

Authors:  Y S Chung; T Sawada; Y Kondo; K Hirayama; A Inui; Y Yamashita; B Nakata; T Okamura; H Ochi; J J Ho; Y S Kim; M Sowa
Journal:  Jpn J Cancer Res       Date:  1997-04

7.  Recent Advances in Point-of-Care Diagnostics for Cardiac Markers.

Authors:  H B Wu Alan
Journal:  EJIFCC       Date:  2014-09-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.